Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05745207 · ClinicalTrials.gov registry record · Phase 1
A Study To Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of E2086 in Healthy Adult and Elderly Participants
A Phase 1 study, sponsored by Eisai.
- Completed
- Registry status
- Phase 1
- Development phase
- 53
- Enrollment target
NCT05745207 is a Phase 1 study that has completed, run by Eisai. The registered enrollment target is 53 participants.
The verdict
NCT05745207, a Phase 1 study, has completed, sponsored by Eisai.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 53 participants
- Enrollment target
Study Summary
The primary objective of this study is to evaluate the safety and tolerability of E2086 following administration of a single oral doses in healthy adult and elderly participants.
Interventions
- DRUG Placebo
- DRUG E2086
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 53 participants |
| Start Date | 2023-02-20 |
| Est. Completion | 2024-01-18 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05745207
The ClinicalTrials.gov registry entry for NCT05745207 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 53 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eisai, which has 287 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT05745207 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05745207 about?
NCT05745207 is a clinical study titled "A Study To Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of E2086 in Healthy Adult and Elderly Participants". The primary objective of this study is to evaluate the safety and tolerability of E2086 following administration of a single oral doses in healthy adult and elderly participants.
What is the current status of trial NCT05745207?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 53 participants. The study started on 2023-02-20. Estimated completion is 2024-01-18.
What interventions are being tested in trial NCT05745207?
The interventions under investigation include: Placebo (DRUG), E2086 (DRUG).
Who is sponsoring clinical trial NCT05745207?
This trial is sponsored by Eisai, which has 287 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.